Oral zero-valent-molybdenum nanodots for inflammatory bowel disease therapy

• DOI: 10.1126/sciadv.abp9882
• Publication Date: 2022-09-16T17:58:17Z
• Authors: Chen Zhang; Han Wang; Xinhui Yang; Zi Fu; Xiuru Ji; Yifan Shi; Jie Zhong; Weiguo Hu; Youqiong Ye; Zhengting Wang; Dalong Ni
• Keywords: Molybdenum; 0301 basic medicine; NF-kappa B; Metal Nanoparticles; Colitis; Inflammatory Bowel Diseases; 3. Good health; Disease Models, Animal; Mice; 03 medical and health sciences; Animals; Biomedicine and Life Sciences; Reactive Oxygen Species

Inflammatory bowel disease (IBD) affects millions of people each year. The overproduction reactive oxygen species (ROS) plays a critical role in the progress IBD and will be potential therapeutic target. Here, we synthesize kind oral zero-valent-molybdenum nanodots (ZVMNs) for treatment by scavenging ROS. These ultrasmall ZVMNs can successfully pass through gastric acid then absorbed intestine. It has been verified that down-regulate quantity ROS reduce colitis mouse model without distinct side effects. In addition, RNA sequencing reveals further mechanism protect colon tissues from oxidative stress inhibiting nuclear factor κB signaling pathway reducing production excessive pro-inflammatory factors. Together, offer promising alternative option patients suffering IBD.